产品封面图

MES-SA

收藏
  • 询价
  • 2026年01月17日
    avatar
    15金牌会员
  • 企业认证

    • 详细信息
    • 文献和实验
    • 技术资料
    • 运输方式

      冻存运输

    • 库存

      大量

    • 器官来源

      子宫

    • 细胞形态

      成纤维样

    • 相关疾病

      其他疾病

    • ATCC Number

      CRL-1976™

    • 年限

      56 years

    • 物种来源

    • 是否是肿瘤细胞

      1

    • 生长状态

      贴壁生长

    Designations: MES-SA
    Depositors:  BI Sikic
    Biosafety Level: 1
    Shipped: frozen
    Medium & Serum: See Propagation
    Growth Properties: adherent
    Organism: Homo sapiens
    Morphology: fibroblast

    Source: Organ: uterus
    Disease: uterine sarcoma
    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
    Isolation: Isolation date: 1980
    Tumorigenic: Yes
    DNA Profile (STR): Amelogenin: X
    CSF1PO: 11
    D13S317: 11,13
    D16S539: 11,12
    D5S818: 13
    D7S820: 7,11
    THO1: 6
    TPOX: 8,11
    vWA: 18
    Cytogenetic Analysis: This is a hypo-diploid human cell line with the modal chromosome number of 45 in 48% of cells examined. The rate of polyploidy was 2.7%. There were five or six marker chromosomes present in each cell. Whereas t(5q6p), 10q+, and 14q+ markers were common in all cells examined, the chromosome combination of either double copy N21 lacking M5 (66.7%) or t(21qter--->C--->?)(M5)/single copy N21/minute metacentric (33.3%) distinguishes the two coexisting clones. Both X chromosomes were normal.
    Age: 56 years
    Gender: female
    Ethnicity: Caucasian
    Comments: The MES-SA cell line was established from a surgical tumor specimen obtained at the time of hysterectomy.
    The tumor was described as a poorly differentiated uterine sarcoma.
    Initially, the cells were grown in soft agar, and later they were transferred to muliwell plates.
    The nonepithelial origin of the cells was supported by ultrastructural studies and the absence of staining for mucin.
    The cells are sensitive to a number of chemotherapeutic agents including doxorubicin, dactinomycin, mitomycin C, taxol and bleomycin.
    They are resistant to vinblastine, dacarbazine, cisplatin, melphalan, vincristine, methotrexate and etoposide.
    The multiple drug resistant cell line MES-SA/Dx5 (ATCC CRL-1977 ) was established from MES-SA cells which were grown in the presence of doxorubicin.
    Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
    Temperature: 37.0°C
    Growth Conditions: Newborn calf serum may be substituted for fetal bovine serum.
    Subculturing: Protocol: Remove spent medium, add fresh EDTA solution (0.15 g disodium EDTA, 4.0 g NaCL, 0.28 g sodium bicarbonate, 0.5 g dextrose and 0.2 g KCl dissolved in 500 ml double distilled water). Allow the cells to sit at room temperature for a few minutes, and dislodge the cells by rapping the side of the flask sharply with the palm of your hand. Add fresh medium, aspirate and dispense into new flasks.
    Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:8 is recommended
    Medium Renewal: 2 to 3 times per week
    Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
    Storage temperature: liquid nitrogen vapor phase
    Doubling Time: 22 to 24 hrs
    Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2007
    recommended serum:ATCC 30-2020
    derivative:ATCC CRL-1977
    derivative:ATCC CRL-2274
    References: 23048: Harker WG, et al. Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res. 43: 4943-4950, 1983. PubMed: 6883344

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • MM-GB/SA Rescoring of Docking Poses

      binding modes, but struggle when predicting the corresponding binding affinities. The rescoring of docking poses using the MM-GB/SA technique has emerged as an important computational approach in structure-based lead optimization as it provides

    • 如何应对SA8000带来的影响

      1.政府层次采取的措施 政府方面的对策包括:制定出口可持续发展战略,加快建立可持续发展评估指标体系;建立统一规范的产品认证认可体系;建立SA8000的预警机制,以负责收集、跟踪国外的SA8000的相关措施,建立SA8000信息中心和数据库,研究SA8000对我国主要出口产品的影响,采取积极的应对措施,创造良好的出口环境;发挥行业协会、进出口商会等中介组织的作用;加强对SA8000知识的研究、宣传、培训和普及工作。同时将企业社会责任运动在中国的实施纳入劳动法制轨道,不论对于提高企业国际

    • 化学发光羧基磁珠偶联SA和抗体的实验技术指南

      磁珠偶联链霉亲和素(SA)和抗体的实验方法及偶联实验过程中的一些注意事项。 一、羧基磁珠偶联链霉亲和素(SA)和抗体的原理 EDC通过与磁珠上的羧基进行反应,形成一种促发剂——不稳定的脲衍生物,NHS通过形成更稳定的酯而增强碳二亚胺交联产物的稳定性。交联过程中EDC、NHS不进入最终产物中,而是转变成水溶性的脲衍生物。 二、羧基磁珠偶联链霉亲和素(SA)  1. 偶联条件 1.1. 活化剂:EDC和NHS 1.2. 反应温度:37℃环境 1.3. 反应时间:    

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    ATCC细胞库
    2026年01月17日询价
    ¥500
    北京百奥创新科技有限公司
    2025年07月06日询价
    ¥800
    上海康朗生物科技有限公司
    2025年07月14日询价
    ¥800
    上海沪震实业有限公司
    2025年07月15日询价
    ¥680
    上海联迈生物工程有限公司
    2025年08月25日询价
    MES-SA
    询价